- ►annals.org K Imrie, R Esmail, RM Meyer… - Annals of internal medicine, 2002 - Am Coll Physicians The Hematology Disease Site Group of the Cancer Care Ontario Practice Guidelines Initiative
has systematically reviewed the published literature and, through a consensus process, developed
an evidence-based practice guideline assessing the role of stem-cell transplantation in ... Cited by 32 - Related articles - BL Direct - All 4 versions
S Brugnatelli, A Riccardi, G Ucci, O Mora, L … - British journal of …, 1996 - pubmedcentral.nih.gov In a multicentre study, 83 patients with advanced and previously uniformly treated multiple myeloma
(MM) were randomised between cyclophosphamide (600 mg m-2) and epirubicin (70 mg
m-2), administered every 3 weeks for three courses and both associated with prednisone ... Cited by 8 - Related articles - BL Direct - All 4 versions
RE Lenhard Jr, LA Kalish, MM Oken, DS … - CA A Cancer Journal … - interscience.wiley.com It is also possible that your web browser is not configured or not able to display style sheets.
In this case, although the visual presentation will be degraded, the site should continue to be
functional. We recommend using the latest version of Microsoft or Mozilla web browser to ... Cited by 10 - Related articles - BL Direct - All 4 versions
RA Kyle, BR Seligman, HJ Wallace Jr, RT Silver, … - … reports. Part 1 - ncbi.nlm.nih.gov A prospective randomized study of the effects of two different therapeutic regimens was conducted
in 41 patients with multiple myeloma resistant to therapy with melphalan. The results of treatment
with cyclophosphamide plus prednisone were compared with those of ... Cited by 11 - Related articles
E Martinez, A Sureda, C De Dalmases, JA … - Bone marrow …, 1996 - cat.inist.fr Fifteen consecutive patients with multiple myeloma(MM) scheduled for peripheral blood progenitor
cell(PBPC) transplantation, were randomly selected to receive cyclophosphamide(CY)(4
g/m 2 ) alone(group I) or associated with recombinant human ... Cited by 12 - Related articles - BL Direct - All 2 versions
RA Kyle, S Gailani, BR Seligman, J Blom, OR … - Cancer treatment …, 1979 - ncbi.nlm.nih.gov Eighty-nine patients with multiple myeloma resistant to melphalan were randomized to receive
cyclophosphamide plus prednisone (CP) (47 patients) or cyclophosphamide plus BCNU plus
prednisone (CBP) (42 patients). No differences were detected in the two groups prior to ... Cited by 21 - Related articles
K Imrie, J Makarski, R Esmail, R Meyer… - Review date: 2003-Oct, 2003 - cancercare.on.ca K. Imrie, J. Makarski, R. Esmail, R. Meyer, and members of the Hematology Disease Site
Group. ... ORIGINAL GUIDELINE: December 22, 2000 MOST RECENT LITERATURE
SEARCH: March 2003 NEW EVIDENCE ADDED TO GUIDELINE REPORT: June 2003 ... Related articles - View as HTML - All 4 versions
M Attal, JL Harousseau - Seminars in hematology, 2001 - Elsevier This article summarizes clinical results of the Intergroupe Francophone du Myélome (IFM)
trials: high-dose therapy (HDT) supported with autologous stem cells improves survival, melphalan
200 mg/m2 is the best preparative regimen, unpurged peipheral blood stem cells (PBSC) ... Cited by 44 - Related articles - BL Direct - All 6 versions
PH Mineur, JF Menard, X Le Loeet, JF … - British journal of …, 1998 - interscience.wiley.com It is also possible that your web browser is not configured or not able to display style sheets.
In this case, although the visual presentation will be degraded, the site should continue to be
functional. We recommend using the latest version of Microsoft or Mozilla web browser to ... Cited by 25 - Related articles - BL Direct - All 5 versions
T Takenaka, K Itoh, T Suzuki, A Utsunomiya, S … - International journal of …, 2004 - Springer Treatment with melphalan and prednisolone (MP) has been the standard regimen for multiple
myeloma (MM) for ... Phase III Study of Ranimustine, Cyclophosphamide, Vincristine,
Melphalan, and Prednisolone (MCNU-COP/MP) versus Modified COP/MP in Multiple ... Cited by 6 - Related articles - BL Direct - All 5 versions
